# Vertex Pharmaceuticals Incorporated – Consensus ‘buy’ rating and 18.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-consensus-buy-rating-and-18.6-upside-potential/4121152555
- Published: 2024-04-19T13:59:46+01:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 25 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $574.00 and $325.00 calculating the average
target price we see $466.14. Given that the stocks previous close was at $393.10
this is indicating there is a potential upside of 18.6%. It’s also worth noting 
that there is a 50 day moving average of $414.21 while the 200 day moving average
is $381.88. The total market capitalization for the company now stands at 101.70B.
The current share price for the company is: $393.48 USD

 The potential market cap would be $120,594,548,757 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 28.33, revenue per share of $38.30
and a 13.17% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on:
